Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 4

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4

Interventions

venetoclax 304Cyclophosphamide 229Cytarabine 199Azacitidine 187fludarabine 180Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 81Rituximab 78Daunorubicin 77Dexamethasone 75Vincristine 68Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 57Tacrolimus 55Etoposide 52ibrutinib 51blinatumomab 51Granulocyte Colony-Stimulating Factor 51Busulfan 50obinutuzumab 49Prednisone 49Melphalan 48acalabrutinib 45Idarubicin 45Stem Cell Transplantation 44Injections 44Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Chlorambucil × Other hematologic neoplasm × 1 year × Clear all
NCT03462719 2026-05-08

GLOW

Janssen Research & Development, LLC

Phase 3 Active not recruiting
211 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca

Phase 3 Active not recruiting
155 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Hoffmann-La Roche

Phase 3 Completed
445 enrolled 22 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

Acerta Pharma BV

Phase 3 Active not recruiting
535 enrolled 19 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡